MENU
+Compare
REGN
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$681.58
Change
-$11.65 (-1.68%)
Capitalization
74.9B

REGN Regeneron Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of medicines for the treatment of serious medical conditions

Industry Biotechnology
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for REGN with price predictions
Jan 14, 2025

REGN's RSI Oscillator climbs out of oversold territory

The RSI Indicator for REGN moved out of oversold territory on December 23, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In of the 25 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in of 318 cases, the price rose further within the following month. The odds of a continued upward trend are .

REGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on January 14, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on REGN as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for REGN entered a downward trend on January 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.554) is normal, around the industry mean (14.746). P/E Ratio (16.858) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (1.051) is also within normal values, averaging (1.852). REGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (5.666) is also within normal values, averaging (263.573).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. REGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

REGN is expected to report earnings to fall 9.55% to $11.27 per share on February 04

Regeneron Pharmaceuticals REGN Stock Earnings Reports
Q4'24
Est.
$11.27
Q3'24
Beat
by $0.74
Q2'24
Beat
by $0.95
Q1'24
Missed
by $0.64
Q4'23
Beat
by $1.09
The last earnings report on October 31 showed earnings per share of $12.46, beating the estimate of $11.72. With 1.11M shares outstanding, the current market capitalization sits at 74.90B.
A.I. Advisor
published General Information

General Information

a developer of medicines for the treatment of serious medical conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
777 Old Saw Mill River Road
Phone
+1 914 847-7000
Employees
13450
Web
https://www.regeneron.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

REGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with IDYA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-1.68%
IDYA - REGN
41%
Loosely correlated
-2.38%
VRTX - REGN
37%
Loosely correlated
+1.21%
INVA - REGN
36%
Loosely correlated
+0.70%
CRNX - REGN
36%
Loosely correlated
+2.38%
NTLA - REGN
35%
Loosely correlated
+0.85%
More